Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01581866 | Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions | PHASE1 | COMPLETED | 56 | — | — | Nov 1, 2004 | Jan 1, 2005 | Apr 20, 2012 | 1 | United States |
| NCT01581879 | Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions | PHASE1 | COMPLETED | 38 | — | — | Nov 1, 2004 | Jan 1, 2005 | Apr 20, 2012 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Ziprasidone HCL Capsules, 20 mg | EXPERIMENTAL | Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited |
| Geodon Capsules, 20 mg | EXPERIMENTAL | Geodon Capsules, 20 mg of Pfizer Inc |
| Name | Type | Description |
|---|---|---|
| Ziprasidone Hydrochloride | DRUG | Ziprasidone HCL Capsules, 20 mg |
Inclusion Criteria: * Male or female, smoker or non-smoker, 18 years of age and older. * Capable of consent. * BMI between 19.0 and 30.0 kg/m2 inclusively. Exclusion Criteria: * Clinically significant illnesses within 4 weeks prior to the administration of the study medication. * Clinically signi...